Thinner and wiser? Prospects of GLP-1 agonists in psychiatry

Publication date

2025-10-23T15:47:35Z

2025-05-22

2025-10-23T15:47:35Z

info:eu-repo/date/embargoEnd/2026-05-21

Abstract

In recent years, growing scientific attention has converged on the intricate, bidirectional relationship between physical health and mental well-being. Chronic inflammation, disruptions in the gut–brain axis and microbiota, and metabolic alterations such as obesity and type 2 diabetes have all been implicated in the pathophysiology of neuropsychiatric disorders. These insights are not merely academic—they are transforming how we approach, frame, and treat neuropsychiatric disorders.

Document Type

Article


Accepted version

Language

English

Publisher

Elsevier B.V.

Related items

Versió postprint del document publicat a: https://doi.org/10.1016/j.euroneuro.2025.05.006

European Neuropsychopharmacology, 2025, vol. 97, p. 3-4

https://doi.org/10.1016/j.euroneuro.2025.05.006

Recommended citation

This citation was generated automatically.

Rights

cc-by-nc-nd (c) Elsevier B.V., 2025

http://creativecommons.org/licenses/by-nc-nd/4.0/